Moderna CEO Worries About Drug Development Overall After US FDA mRNA-1010 Refusal-To-File

 
• By Alaric DeArment
  
Moderna is concerned about the impact of its RTF on the regulatory landscape. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Vaccines

More from United States